



PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 11/20/14
LAST REVIEW DATE: 11/15/18
LAST CRITERIA REVISION DATE: 11/15/18
ARCHIVE DATE:

SIVEXTRO™ (tedizolid phosphate) oral tablet ZYVOX® (linezolid) oral suspension and tablet

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as “Description” defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as “Criteria” defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the request form in its entirety with the chart notes as documentation. All requested data must be provided. Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**

**SIVEXTRO™ (tedizolid phosphate) oral tablet
ZYVOX® (linezolid) oral suspension and tablet (cont.)**

Criteria:

- **Criteria for initial therapy:** Sivextro or Zyvox is considered **medically necessary** for the treatment infections caused by susceptible bacteria with medical record documentation of **ALL** of the following:
1. Diagnosis is **ONE** of the following:
 - **For Sivextro:** proven or strongly suspected acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria for individuals 18 years of age or older
 - **For Zyvox:** proven or strongly suspected clinical infection caused by susceptible bacteria per manufacturer label
 - When applicable, individual is transitioning intravenous therapy to oral therapy to facilitate a hospital discharge
 2. Culture was obtained from **ONE** of the following:
 - **For Sivextro:** skin or skin structure (not from sputum, blood, or other site)
 - **For Zyvox:** skin, skin structure, blood, or sputum
 3. Proven or strongly suspected micro-organism is **ONE** of the following:
 - Methicillin resistant *Staphylococcus aureus* (MRSA)
 - Methicillin resistant *Staphylococcus epidermidis* (MRSE)
 - *Enterococcus faecalis* (Vancomycin resistant)
 - *Enterococcus faecium* (Vancomycin resistant)
 - Vancomycin intermediate *Staphylococcus aureus* (VISA)
 - Vancomycin resistant *Staphylococcus aureus* (VRSA)
 4. Individual has failure, contraindication, or intolerance to linezolid
 5. Will not be used in the following situations:
 - **For Sivextro:**
 - Use in a patient on an mono-amine oxidase inhibitor (MAOI)
 - Use in a patient taking serotonergic agents including serotonin re-uptake inhibitors, tricyclic antidepressants, serotonin 5-HT₁ receptor agonists (triptans), meperidine, or buspirone
 - **For Zyvox:**
 - Use in a patient with known hypersensitivity to linezolid or any of the other components of the product (a contraindication)
 - Use with or within two weeks of a MAOI (a contraindication)
 - Use in a patient taking serotonergic agents including serotonin re-uptake inhibitors, tricyclic antidepressants, serotonin 5-HT₁ receptor agonists (triptans), meperidine, bupropion, or buspirone
 - Use in a patient taking pseudoephedrine or phenylpropanolamine

**SIVEXTRO™ (tedizolid phosphate) oral tablet
ZYVOX® (linezolid) oral suspension and tablet (cont.)**

Approval duration:

▪ **For Sivextro:**

- One tablet daily for 6 days total (includes number of in-patient IV use)
- **IV infusion or injections** – MEDICAL BENEFIT ONLY
- No refills will be authorized
- Any request for refill will be reviewed as a new request

▪ **For Zyvox:**

- Two tablets daily for 14 days total (includes number of in-patient IV use) for most infections
- Two tablet daily for 28 days total (includes number of in-patient IV use) for Vancomycin resistant *Enterococcus faecium* infections
- **IV infusion or injections** – MEDICAL BENEFIT ONLY
- No refills will be authorized
- Any request for refill will be reviewed as a new request

Description:

This Pharmacy Coverage Guideline applies to the out-patient use of Sivextro and Zyvox, and should not be utilized for any other purpose.

Zyvox (linezolid) and Sivextro (tedizolid) are oxazolidinone-class antimicrobials used for the treatment of infections caused by susceptible isolates of gram-positive microorganisms. They should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, this information should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Prescribing either agent in the absence of a proven or strongly suspected bacterial infection or prophylactic indication is unlikely to provide benefit to the individual and increases the risk of the development of drug-resistant bacteria.

Acute bacterial skin and skin structure infections (ABSSSI) may include cellulitis, erysipelas, wound infections, burns, and major cutaneous abscesses. ABSSSI may present with redness, edema, or induration with lymph node enlargement, purulent drainage or pus within the dermis, and systemic symptoms such as fever.

Common bacterial pathogens causing ABSSSI are *Streptococcus pyogenes* and *Staphylococcus aureus* including methicillin-resistant *Staphylococcus aureus* (MRSA). Less common causes include other *Streptococcus species*, *Enterococcus faecalis*, *Enterococcus faecium*, and Gram-negative bacteria. The incidence of gram positive ABSSSI that requires hospitalization has increased along with an increase in antimicrobial resistant organisms. MRSA has become a common cause of ABSSSI infections and pneumonia in the hospital setting. Infections in individuals who lack the usual risk factors for MRSA have also emerged in the community. As a result, community associated MRSA (CA-MRSA) are now a common cause of ABSSSI. Over reliance with use of Vancomycin has in addition resulted in emergence of resistant strains of certain bacteria such as Vancomycin resistant *Staphylococcus aureus* (VRSA), Vancomycin intermediate *Staphylococcus aureus* (VISA), and Vancomycin resistant *Enterococcus* (VRE).

**SIVEXTRO™ (tedizolid phosphate) oral tablet
ZYVOX® (linezolid) oral suspension and tablet (cont.)**

As a result of rising prevalence of MRSA, empiric therapy for hospitalized individuals with ABSSSI usually includes intravenous use of an antimicrobial with activity against MRSA and an agent that has activity for the other possible pathogens. Out-patients may be managed with a cost effective oral agent.

The approach to treatment ABSSSI and pneumonia and antimicrobial selection is guided by manifestation of infection, severity of clinical presentation, location of infection, and results of culture and sensitivities. Other variables to consider in antimicrobial selection include cost, patient risk factors, drug interaction potential, efficacy and safety, monitoring requirements, likely pathogens, and local resistance patterns.

An adequate clinical specimen should be obtained prior to the start of treatment for culture, gram stain, and *in vitro* susceptibility testing. This is an important step for describing the underlying bacterial etiology of the infection. Once these results are known, it may be possible to narrow or change empiric antimicrobial therapy to one that is more cost effective and one that has specific activity for the particular micro-organism present. Depending upon agent chosen, this may allow for transition from intravenous to oral therapy to facilitate discharge to home for hospitalized individuals who are clinically stable to do so.

Numerous antimicrobials are available for treatment of ABSSSI that have activity against gram positive bacteria (including MRSA) as well as the some of the other pathogens involved in the infection. These include Vancomycin (IV, generic), Daptomycin IV (Cubicin), Dalbavacin IV (Dalavance), Oritavancin IV (Orbactiv), Telavancin IV (Vibativ), Ceftaroline IV (Teflaro), Tigecycline IV (Tygacil), Doxycycline (IV and PO, generic), Minocycline (IV and PO), Clindamycin (IV and PO, generic), Trimethoprim-Sulfamethoxazole (IV and PO, generic), Linezolid IV and PO (Zyvox), and Tedizolid IV and PO (Sivextro).

Other antimicrobial agents used for pneumonia can include Amoxicillin + Clavulanate, Cephalosporins, Fluoroquinolone (Levofloxacin, Gemifloxacin, Moxifloxacin, Ofloxacin), Clindamycin, Trimethoprim-sulfamethoxazole, Doxycycline, Minocycline, and Macrolide (Azithromycin, Erythromycin, Clarithromycin).

Both Tedizolid and Linezolid can be administered orally or intravenously. A short 6-day course of Tedizolid has been shown to be statistically non-inferior to a 10-day course of Linezolid for both early and sustained clinical responses in patients with ABSSSIs.

Definitions:

ABSSSI

A bacterial infection of the skin with a lesion size area of at least 75 cm² (measured by the area of redness, edema, or induration).

The following infections are defined as ABSSSIs:

Cellulitis/erysipelas: a diffuse skin infection characterized by spreading areas of redness, edema, and/or induration

Wound infection: an infection characterized by purulent drainage from a wound with surrounding redness, edema, and/or induration

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 11/20/14
LAST REVIEW DATE: 11/15/18
LAST CRITERIA REVISION DATE: 11/15/18
ARCHIVE DATE:

**SIVEXTRO™ (tedizolid phosphate) oral tablet
ZYVOX® (linezolid) oral suspension and tablet (cont.)**

Major cutaneous abscess: an infection characterized by a collection of pus within the dermis or deeper that is accompanied by redness, edema, and/or induration

Spectrum of Activity:

Sivextro (tedizolid):

Activity against the following, shown by *in vitro* and clinical infections:

Enterococcus faecalis
Staphylococcus aureus (includes methicillin resistant (MRSA) & methicillin susceptible (MSSA) isolates)
Streptococcus pyogenes
Streptococcus agalactiae
Streptococcus anginosus
Streptococcus intermedius
Streptococcus constellatus

Activity against the following, shown by *in vitro* data:

Enterococcus faecium
Staphylococcus epidermidis [includes methicillin resistant (MRSE) & methicillin susceptible (MSSE)]
Staphylococcus haemolyticus
Staphylococcus lugdunensis
Streptococcus pneumonia

Zyvox (linezolid):

Activity against the following, shown by *in vitro* and clinical infections:

Enterococcus faecium (Vancomycin resistant isolates only)
Staphylococcus aureus (includes MRSA isolates)
Streptococcus pyogenes
Streptococcus agalactiae
Streptococcus pneumonia

Activity against the following, shown by *in vitro* data:

Enterococcus faecalis (includes Vancomycin resistant isolates)
Enterococcus faecium (Vancomycin susceptible isolates)
Staphylococcus epidermidis (includes MRSE isolates)
Staphylococcus haemolyticus
Viridans group streptococci

Other potential oral anti-microbial therapy for ABSSSI or Pneumonia (dependent on manifestation of infection, severity and location of infection, and results of culture and sensitivities):

Amoxicillin + Clavulanate
Dicloxacillin
Cephalosporin
Fluoroquinolone (Levofloxacin, Gemifloxacin, Moxifloxacin, Ofloxacin)
Clindamycin
Trimethoprim-sulfamethoxazole
Doxycycline

**PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS**

**ORIGINAL EFFECTIVE DATE: 11/20/14
LAST REVIEW DATE: 11/15/18
LAST CRITERIA REVISION DATE: 11/15/18
ARCHIVE DATE:**

**SIVEXTRO™ (tedizolid phosphate) oral tablet
ZYVOX® (linezolid) oral suspension and tablet (cont.)**

Minocycline
Macrolide (Azithromycin, Erythromycin, Clarithromycin)

Resources:

Sivextro package insert. Revised by manufacturer on 08-2017. Accessed on 10-26-17.

Zyvox package insert. Revised by manufacturer on 05-2017. Accessed on 10-26-17.

Linezolid package insert. Revised by manufacturer on 03-2016. Reviewed on 07-10-2017

Sivextro package insert. Revised by manufacturer on 10-2016. Reviewed on 07-10-2017

Sivextro. Package Insert. Revised by manufacturer 07/2015. Accessed 05-23-2016.

Sivextro. Package Insert. Reference ID 3529436. Revised by manufacturer 06/2014. Accessed 10-22-2014.

Zyvox. Package Insert. Revised by manufacturer 07/2015. Accessed 05-23-2016.

Zyvox. Package Insert. Reference ID 3441619. Revised by manufacturer 09/2013. Accessed 10-22-2014.

Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 Update by the Infectious Disease Society of America. CID 2014 DOI: 10.1093/cid/ciu296



An Independent Licensee of the Blue Cross and Blue Shield Association

Fax completed prior authorization request form to 602-864-3126 or email to pharmacyprecert@azblue.com. Call 866-325-1794 to check the status of a request. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at www.azblue.com/pharmacy.

Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently.

REQUIRED: Office notes, labs, and medical testing relevant to the request that show medical justification are required.

Member Information			
Member Name (first & last):	Date of Birth:	Gender:	BCBSAZ ID#:
Address:	City:	State:	Zip Code:

Prescribing Provider Information			
Provider Name (first & last):	Specialty:	NPI#:	DEA#:
Office Address:	City:	State:	Zip Code:
Office Contact:	Office Phone:	Office Fax:	

Dispensing Pharmacy Information		
Pharmacy Name:	Pharmacy Phone:	Pharmacy Fax:

Requested Medication Information			
Medication Name:	Strength:	Dosage Form:	
Directions for Use:	Quantity:	Refills:	Duration of Therapy/Use:

Check if requesting **brand** only Check if requesting **generic**

Check if requesting continuation of therapy (prior authorization approved by BCBSAZ expired)

Turn-Around Time For Review	
<input type="checkbox"/> Standard <input type="checkbox"/> Urgent. Sign here: _____	<input type="checkbox"/> Exigent (requires prescriber to include a written statement)

Clinical Information	
1. What is the diagnosis? Please specify below. ICD-10 Code: _____ Diagnosis Description: _____	
2. <input type="checkbox"/> Yes <input type="checkbox"/> No	Was this medication started on a recent hospital discharge or emergency room visit?
3. <input type="checkbox"/> Yes <input type="checkbox"/> No	There is absence of ALL contraindications.

4. What medication(s) has the individual tried and failed for this diagnosis? Please specify below.
Important note: Samples provided by the provider are not accepted as continuation of therapy or as an adequate trial and failure.

Medication Name, Strength, Frequency	Dates started and stopped or Approximate Duration	Describe response, reason for failure, or allergy

5. Are there any supporting labs or test results? Please specify below.

Date	Test	Value

Pharmacy Prior Authorization Request Form

6. Is there any additional information the prescribing provider feels is important to this review? Please specify below.
For example, explain the negative impact on medical condition, safety issue, reason formulary agent is not suitable to a specific medical condition, expected adverse clinical outcome from use of formulary agent, or reason different dosage form or dose is needed.

Signature affirms that information given on this form is true and accurate and reflects office notes

Prescribing Provider's Signature: _____ Date: _____

Please note: Some medications may require completion of a drug-specific request form.

Incomplete forms or forms without the chart notes will be returned.

Office notes, labs, and medical testing relevant to the request that show medical justification are required.